Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

October 8, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Cutaneous Squamous Cell CarcinomaAdvanced Cutaneous Squamous Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma
Interventions
DRUG

Cemiplimab

Cemiplimab administered intravenously

BIOLOGICAL

RP1

RP1 administered intratumorally

Trial Locations (56)

10065

Memorial Sloan Kettering Cancer Center, New York

10117

Charite Universitatsmedizin Berlin, Berlin

11527

Hippocratio General Hospital of Athens, Athens

12462

Attiko University Hospital, Athens

16121

Andreas Syggros Hospital, Athens

20251

Universitätsklinikum Eppendorf, Hamburg

25000

CHU Besancon - Hopital Jean Minjoz, Besançon

27599

University Of North Carolina at Chapel Hill, Chapel Hill

29605

Prisma Health Cancer Institute, Greenville

30120

Hospital Universitario Virgen de la Arrixaca, Murcia

30322

Winship Cancer Institute of Emory University, Atlanta

32806

Orlando Health UF Health Cancer Center, Orlando

33136

University of Miami Health System, Miami

33612

Moffitt McKinley Outpatient Center, Tampa

38700

CHU de Grenoble - Hopital A Michallon, La Tronche

43210

Ohio State University Comprehensive Cancer Center, Columbus

45147

Universitatsklinikum Essen, Essen

46014

Hospital General Universitario De Valencia, Valencia

59037

CHRU de Lille, Lille

69120

Universitatsklinikum Heidelberg: National Centre for Tumour Diseases (NCT), Heidelberg

69310

Hospices Civils de Lyon, Pierre-Bénite

69373

Centre Léon Bérard, Lyon

72074

Universitatsklinikum Tubingen Zentrum fur Dermatoonkologie, Tübingen

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

80337

University Hospital Munchen (LMU), München

90024

University of California Los Angeles, Los Angeles

92093

University of California San Diego, La Jolla

94305

Stanford University, Stanford

94805

Institut Gustave Roussy, Villejuif

07601

John Theurer Cancer Center at Hackensack Univeristy Medical Center, Hackensack

Unknown

Chris O'Brien Lifehouse, Camperdown

Cancer Care Wollongong Pty Limited, Wollongong

Tasman Oncology Research Ltd, Southport

Monash Medical Centre, Clayton

Peter MacCallum Cancer Centre, Melbourne

The Alfred Hospital, Melbourne

Sir Charles Gairdner Hospital, Nedlands

"Multiprofile Hospital for Active Treatment - Uni Hospital OOD Department of Medical Oncology", Panagyurishte

"Complex Oncology Center - Plovdiv EOOD Department of Medical Oncology and Cutaneous Cancer Diseases ", Plovdiv

CHU Dijon Hopital F. Mitterrand Service de Dermatologie - UMAC, Dijon

Service de Dermatologie et Cancerologie Cutanee Hopital de la Timone, Marseille

Hospital Saint Louis, Paris

"General Hospital of Athens Laiko, 1st Department of Medicine, University of Athens Medical School", Athens

"Istituto Tumori Giovanni Paolo II IRCCS", Bari

Klinika Dermatologii, Wenerologii i Alergologii, USK im J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Fundación Jiménez Díaz, Madrid

Clinica Universitaria de Navarra, Pamplona

M4N 3M5

Sunnybrook Health Science Centre, Toronto

06202

CHU Nice - Hopital de l'Archet 2, Nice

80-214

Uniwersyteckie Centrum Kliniczne; Centrum Leczenia Czerniaka w Gdańsku, Gdansk

31-115

Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy Oddzial w Krakowie, Krakow

02-781

Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy, Warsaw

08036

Hospital Clinic Barcelona, Barcelona

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Replimune Inc.

INDUSTRY